The FDA has accepted Takeda Pharmaceutical's NDA for alogliptin, a DPP-4 inhibitor for type 2 diabetes. The FDA's acceptance of the NDA filing triggers a $15 million milestone payment to PPD. Release
The FDA has accepted Takeda Pharmaceutical's NDA for alogliptin, a DPP-4 inhibitor for type 2 diabetes. The FDA's acceptance of the NDA filing triggers a $15 million milestone payment to PPD. Release